Zolmigren nasal spray 2.5 mg/dose, 2 ml (20 doses)— Made in Ukraine — Free Delivery

Brand: Farmak
Product Code: Zolmigren nasal spray 2.5 mg
Availability: In Stock

$39.57

Add to Cart

Description

Product description

Zolmigren is prescribed for the relief of a migraine attack with and without aura.

Structure

active substance: zolmitriptan;

1 dose contains zolmitriptan 2.5 mg

Excipients: benzalkonium chloride, citric acid, acid; sodium phosphate, dihydrate; dexpanthenol; purified water.

The anti-migraine agent Zolmitriptan is a selective agonist of recombinant 5-HT1B / 1D human vascular serotonin receptors. Has a moderate affinity with serotonin 5-HT 1A receptors, does not have significant affinity or pharmacological activity for 5HT2-, 5HT3-, 5HT4-serotonin receptors, a1-, a2-, b1-adrenergic receptors, H1, H2-receptors, M-choline receptors, D1-, D2-dopamine receptors.

Contraindications

hypersensitivity to preparation components
uncontrolled arterial hypertension;
ischemic heart disease, including a history of myocardial infarction
angiospastic angina (Prinzmetal's angina)
ischemic stroke or transient ischemic attack and migraine attacks, accompanied by hemiplegia and a history of basilar disorders
concomitant use of ergotamine, ergotamine derivatives or other 5HT1B / 1D receptor agonists;
peripheral arterial disease
simultaneous use of MAO-A inhibitors and within 14 days after their cancellation;
Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory pathways of the heart.
Interaction with other medicinal products and other types of interactions
In studies of the interaction of zolmitriptan with caffeine, ergotamine, dihydroergotamine, paracetamol, metoclopramide, pizotifen, fluoxetine, rifampicin and propranolol, no clinically significant changes in the pharmacokinetic parameters of zolmitriptan and its active metabolite were found.

Application features

Application during pregnancy or lactation

The safety of using zolmitriptan during pregnancy has not been studied. Therefore, the use of Zolmigren® spray for pregnant women is possible only when the expected therapeutic effect for the mother outweighs the potential risk to the fetus / child.

There is no data on the penetration of zolmitriptan into breast milk. Therefore, women who are breastfeeding should use the preparation only when the expected therapeutic effect for the mother outweighs the potential risk for the child. Animal studies have shown that when taken orally, zolmitriptan is 4 times higher in milk than in blood plasma.

Children

The efficacy and safety of the preparation in children have not been established, therefore it is not recommended to use it in this age group.

The ability to influence the reaction rate when driving or driving other mechanisms

During the research, it was found that oral administration of zolmitriptan at a dose of 20 mg does not affect the results of psychomotor tests. However, patients whose activities require the speed of psychomotor reactions are advised to take into account the possible development of drowsiness and other symptoms of migraine.

Method of administration and dosage

Zolmigren® spray is not intended for use in the prevention of migraine attacks. After the onset of a migraine attack, it is recommended to use the preparation as soon as possible. The initial recommended dose is 2.5 mg, which corresponds to one spray of Zolmigren® spray at a dosage of 2.5 mg / dose. The maximum recommended dose is 5 mg, which corresponds to one spray of Zolmigren® spray at a dosage of 5 mg / dose or two sprays at a dosage of 2.5 mg / dose. In the absence of effect or in case of relapse of pain, repeated administration is possible, but not earlier than 2:00 after the first dose. The maximum daily dose is 10 mg.

No dose adjustment is required for patients with mild hepatic impairment. It is not recommended to use the preparation in patients with moderate and severe hepatic impairment.

For interactions requiring dose adjustment, see the section "Interaction with other medicinal products and other forms of interaction".

Instructions for use.

For greater effectiveness of the Zolmigren® spray spray, you should clear your nostrils (blow your nose gently) before using it.

Before using the preparation for the first time, press the sprayer several times, directing the spray into the air, until a uniform spray cloud is formed. The preparation is now ready for use.

If more than four weeks have passed since the last use of the preparation, the first spraying should be done in the air to prevent the use of an incomplete dose. In the period between use, the vial with the preparation should be stored with a tightly closed cap.

When using the bottle, hold the spray up.

Tilt your head slightly forward, insert the spray into the nostril, slightly tilting the tip of the spray from the center of the nose, and make one press. If necessary, repeat the same with the other nostril.

Overdose

Symptoms: The volunteers who took a single oral dose of zolmitriptan at a dose of 50 mg had a sedative effect. Patients should be monitored in case of overdose for at least 15 hours or until symptoms or signs disappear.

Treatment: symptomatic and supportive therapy.

Adverse Reactions

On the part of the cardiovascular system: palpitations; arrhythmia; tachycardia lability of blood pressure myocardial infarction angina pectoris coronary spasm.

From the side of the central and peripheral nervous system: impaired sensitivity, dizziness, headache, hyperesthesia, paresthesia, drowsiness, fever, loss of consciousness, depression, insomnia, convulsions, nervous agitation, anxiety, amnesia, tinnitus, hallucinations, coma, hyperthermia , Raynaud's syndrome, cerebrovascular disorders, including stroke.

From the digestive system: abdominal pain, nausea, vomiting, dry mouth ischemia and infarction of the gastrointestinal vessels (clinical manifestations are abdominal pain and diarrhea mixed with blood or pain in the abdominal cavity), spleen infarction, dyspepsia, dysphagia.

From the genitourinary system: polyuria, frequent urination, urge to urinate.

From the musculoskeletal system: muscle weakness, muscle pain.

From the immune system: hypersensitivity reactions, including urticaria, angioedema and anaphylactic / anaphylactoid reactions.

From the respiratory system: bronchitis, increased cough, shortness of breath, epistaxis, laryngeal edema, pharyngitis, rhinitis, sinusitis.

From the side of the organ of vision: conjunctivitis, dry eyes, visual field defect.

General disorders: asthenia, feeling of heaviness, constriction, pain or pressure in the throat, neck, chest and limbs, excessive sweating.

Certain symptoms may belong to the migraine itself.

Storage conditions

Store at a temperature not exceeding 30 ° C in its original packaging. Do not freeze.

Keep out of the reach of children.

Shelf life is 2 years.

2 reviews

User

13/12/2020

text_comment

Thank you so much. Fast delivery

User

14/11/2020

text_comment

thank you